October 3, 2019 7:52pm

Remember Icarus, his wings were made of wax and melted as he flew higher to the sun

Q4 could be a serious disruptor as it ends the year ‘19

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.


 

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

 

The Dow closed up +65.48 (+0.25%), the S&P closed up +22.23 (+0.80%) and the NASDAQ closed up +87.02 (+1.12%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed up +1.55% while the XBI closed up +1.51%
  • Wednesday the IBB closed down -0.78% while the XBI closed up +0.68%
  • Tuesday the IBB closed down -1.50% while the XBI closed down -1.64%
  • Monday the IBB closed up +0.20% while the XBI closed down -0.21%

 

Henry’omics:

Sector equities rose to a neutral station while market indexes rose on Thursday, recovering some of the losses from a steep two-day sell-off amid increasing expectations that the Federal Reserve will cut rates later this month.

 

The advance/decline line scenario of 45 covered companies:  

  • Thursday the close was neutral with an A/D line of 21/21, 1 flat and 2 acquired;
  • Wednesday the close was negative with an A/D line of 18/22, 3 flats and 2 acquired;
  • Tuesday the close was negative with an A/D line of 5/36, 2 flats and 2 acquired;
  • Monday the close was positive with an A/D line of 21/19, 3 flats and 2 acquired;

 

Decliners:

  • ReNeuron (RENE.L -$38.00 after Wednesday’s -$64.00, Tuesday’s -$20.00 and Monday’s +$17.50);
  • bluebird bio (BLUE -$0.96 after Wednesday’s -$0.57,Tuesday’s -$4.80 and Monday’s -$0.99);
  • Mesoblast (MESO -$0.50);
  • Vericel (VCEL -$0.35);
  • CRISPER Therapeutics (CRSP -$0.30);

Incliners:

  • Sage Therapeutics (SAGE +$5.00 after Wednesday’s +$1.25, Tuesday’s -$4.01 after Monday’s -$2.46);
  • uniQure (QURE +$3.11);
  • Regenxbio (RGNX +$1.62 after Wednesday’s +$0.98);
  • Global Blood Therapeutics (GBT +1.58);
  • Ultragenyx (RARE +$1.32);

 

The percentage (%) indicators: 

  • Thursday’s range of the 21 upside was +0.17% (NTLA) to +8.93% (VSTM) while the 21 downside ranged from -0.35% (SGMO) to -18.45% (RENE.L);
  • Wednesday’s range of the 18 upside was +0.35% (SGMO) to +7.78% (XON) while the 22 downside ranged from -0.21% (ONCE) to -23.70% (RENE.L);
  • Tuesday’s range of the 5 upside was +1.20% (CUR) to +8% (RENE.L) while the 36 downside ranged from -0.13% (ONCE) to -9.62% (BSTG);
  • Monday’s range of the 21 upside was +0.22% (FIXX) to +7.53% (RENE.L) while the 20 downside ranged from -0.43% (QURE) to -30.65% (HSGX);

 

Upside volume stats:  to compare

  • Thursday: 4 out of the 21 upside had higher than the 3 month average volume
  • Wednesday: 8 out of the 18 upside had higher than the 3 month average volume
  • Tuesday: 3 out of the 5 upside had higher than the 3 month average volume;
  • Monday: 9 out of the 21 upside had higher than the 3 month average volume;

Downside volume stats:

  • Thursday: 9 out of the 21 downside had higher than the 3 month average volume;
  • Wednesday: 15 out of the 22 downside had higher than the 3 month average volume;
  • Tuesday: 19 out of the 36 downside had higher than the 3 month average volume;
  • Monday: 4 out of the 19 downside had higher than the 3 month average volume;

 

1 flat – BSTG with 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche is still being delayed (October?)

 

October’s sessions:

Thursday closed NEUTRAL with 21 decliners, 21 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 36 decliners, 5 advancers, 2 flat and 2 acquired (AST & OSIR);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.